The title for the world's top-selling drug is a close contest
The title for the world's top-selling drug is a close contest between oncology blockbusters and the explosive rise of metabolic treatments.
For years, Keytruda (pembrolizumab)—an immunotherapy cancer drug made by Merck—held the undisputed #1 spot worldwide, generating over $29–$31 billion annually. However, anti-diabetes and weight-loss medications (GLP-1 receptor agonists) have experienced the fastest surge in pharmaceutical history, with Eli Lilly's tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) challenging and overtaking traditional leaders.
Why These Drugs Are Best-Sellers
1. Keytruda (Pembrolizumab) — The Long-Reigning Oncology King
- What it is: A breakthrough immunotherapy drug that helps the body's own immune system find and fight cancer cells.
- Why it sells so much:
- Broad Application: It is approved to treat a massive variety of cancers—including lung cancer, melanoma, triple-negative breast cancer, and Hodgkin lymphoma.
- Lifesaving Efficacy: For many late-stage cancer patients, it has drastically extended survival rates, making it a standard-of-care cornerstone in modern oncology globally.
2. Mounjaro / Zepbound (Tirzepatide) & Ozempic / Wegovy (Semaglutide) — The Metabolic Revolution
- What they are: Incretin mimetics (GLP-1 and GIP/GLP-1 receptor agonists) originally created for type 2 diabetes that dramatically suppress appetite and regulate blood sugar.
- Why they sell so much:
- Overwhelming Global Demand: Obesity and type 2 diabetes affect hundreds of millions of people worldwide.
- Secondary Health Benefits: Clinical trials have shown these medications significantly reduce the risk of major cardiovascular events (like heart attacks and strokes), driving massive demand from both physicians and patients seeking preventative health outcomes.
- High Price Points & Scale: Because they are chronic, long-term treatments with widespread cultural and medical adoption, their combined global revenues have skyrocketed into tens of billions of dollars annually.